Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma

Clinical Cancer Research

Volumn 4, Issue 5, 1998, Pages 1183-1191

  Motzer, Robert J ^a   Rakhit, Ashok ^b,d   Schwartz, Lawrence H ^a   Olencki, Thomas ^c   Malone, Thomas M ^a   Sandstrom, Kate ^c   Nadeau, Rosemary ^b,d   Parmar, Harsukh ^b,d   Bukowski, Ronald ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOFFMANN LA ROCHE INC   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

^d ROCHE PRODUCTS LTD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 12;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY CARCINOMA; LEUKOPENIA; LIVER DYSFUNCTION; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; INTERLEUKIN-12; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 0031924595     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Wolf, S. F., Temple, P. A., Kobayashi, M., Young, D., Dicig, M., Lowe, L., Dzialo, R., Fitz, L., Ferenz, C., Hewick, R. M., Kelleher, K., Hermmann, S. H., Clark, S. C., Azzoni, L., Chan, S. H., Trinchieri, G., and Perussia, B. Cloning of cDNA for natural killer cell stimulatory factor, a heterodimeric cytokine with multiple biologic effects on T and natural killer cells. J. Immunol., 146: 3074-3081, 1991.
2. Sieburth, D., Jabs, E. W., Warrington, J. A., Li, X., Lasota, J., LaForgia, S., Kelleher, K., Huebner, K., Wasmuth, J. J., and Wolf, S. F. Assignment of genes encoding a unique cytokine (IL-12) composed of two unrelated subunits to chromosomes 3 and 5. Genomics, 14: 59-62, 1992.
3. Kobayashi, M., Fitz, L., Ryan, M., Hewick, R. M., Clark, S. C., Chan, S., Loudon, R., Sherman, F., Perussia, B., and Trinchieri, G. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J. Exp. Med., 170: 827-845, 1989.
4. Stern, A. S., Podlaski, F. J., Hulmes, J. D., Pan, Y. E., Quinn, P. M., Wolitzky, A. G., Familetti, P. C., Stremlo, D. L., Truitt, T., Chizzonite, R., and Gately, M. K. Purification to homogeneity and partial characterization of cytotoxic lymphocyte maturation factor from human B-lymphoblastoid cells. Proc. Natl. Acad. Sci. USA, 87: 6808-6812, 1990.
5. Banks, R. E., Patel, P. S., and Selby, P. J. Interleukin-12: a new clinical player in cytokine therapy. Br. J. Cancer, 71: 655-659, 1995.
6. Brunda, M. J. Interleukin-12. J Leukocyte Biol., 55: 280-288, 1997.
7. Galetti, T. P. Interleukin-12: a recently discovered cytokine with potential for enhancing cell-mediated immune responses to tumors. Cancer Invest., 11: 500-506, 1993.
8. Brunda, M. J., Luistro, L., Warrier, R. R., Wright, R. B., Hubbard, B. R., Murphy, M., Wolf, S. F., and Gately, M. K. Antitumor and antimetastatic activity of interleukin-12 against murine tumors. J. Exp. Med., 178: 1223-1230, 1993.
9. Voest, E. E., Kenyon, B. M., O'Reilly, M., Truitt, G., Amato, R. J., and Folkman, J. Inhibition of angiogenesis in vivo by interleukin-12. J. Natl. Cancer Inst., 87: 581-586, 1995.
10. Motzer, R. J., Bander, N. H., and Nanus, D. M. Renal-cell carcinoma. New Engl. J. Med., 335: 865-875, 1996.
11. Nastala, C. L., Edington, H. D., McKinney, T. G., Tahara, H., Nalesnik, M. A., Brunda, M. J., Gately, M. K., Wolf, S. F., Schreiber, R. D., Storkus, W. J., and Lotze, M. T. Recombinant IL-12 administration induces tumor regression in association with IFN -γ production. J Immunol., 153: 1697-1706, 1994.
12. Fuchs, D., Hausen, A., Reibnegger, G., Werner, E. R., Dierich, P., and Wachter, H. Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol. Today, 9: 5: 150-158, 1988.
13. Nadeau, R., Ostrowski, C., Ni-Wu, G., and Liberato, D. Pharmacokinetics and pharmacodynamics of recombinant human interleukin-12 (rHuIL-12) in male rhesus monkeys. J. Pharmacol. Exp. Then, 274: 78-83, 1995.
14. Germann, T., Szeliga, J., Hess, H., Storkel, S., Podlaski, F. J., Gately, M. K., Schmitt, E., and Rude, E. Administration of interleukin-12 in combination with type II collagen induces severe arthritis in DBA/1 mice. Proc. Natl. Acad. Sci. USA, 92: 4823-4827, 1995.
15. Trembleau, S., Penna, G., Bosi, E., Mortara, A., Gately, M. K., and Adorini, L. Interleukin 12 administration induces T helper type 1 cells and accelerates autoimmune diabetes in NOD mice. J Exp. Med., 181: 817-821, 1995.
16. Atkins, M. B., Robertson, M. J., Gordon, M., Lotze, M. T., De-Coste, M., DuBois, J. S., Ritz, J., Sandler, A. B., Edington, H. D., Garzone, P. D., Mier, J. W., Canning, C. M., Battiato, L., Tahara, H., and Sherman, M. L. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. Clin Cancer Res., 3: 409-417, 1997.
17. Cohen, J. IL-12 deaths: explanation and a puzzle. Science (Washington DC), 270: 908, 1995.
18. Wigginton, J. M., Komschlies, K. L., Back, T. C., Franco, J. L., Brunda, M. J., and Wiltrout, R. H. Administration of interleukin 12 with pulse interleukin 2 and the rapid and complete eradication of murine renal carcinoma. J. Natl. Cancer Inst., 88: 38-43, 1996.